Company intelligence / Profile preview
Hunterian Medicine
Baltimore, Maryland, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Hunterian Medicine is developing a patented CRISPR delivery platform using a single AAV vector with bidirectional promoter for efficient in vivo gene editing; awarded Therapeutics Development Award by Cystic Fibrosis Foundation for cystic fibrosis program.
- Therapeutic areas
- PulmonologyRare Diseases
- Modalities
- CRISPR-based therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Cystic Fibrosis FoundationInscripta
Beyond the preview
Go deeper on Hunterian Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hunterian Medicine.